BGB-A317-302

Active, not recruiting

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Beigene Study ID info

BGB-A317-302

ClinicalTrials.gov ID info

EudraCT Number info

2017-003699-30

Clinical Drug Trials ID info

CTR20171026

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents